AstraZeneca (LON:AZN)

AstraZeneca (LON:AZN)

Share Price
6,380.00 p
-10 (-0.16 %)
Market Cap
£83,691.76 m
Proactive Investors - Run By Investors For Investors


AstraZeneca is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease. AstraZeneca has over 67,000 empolyees and operates in over 100 countries with growing presence in important emerging markets.

Market: LSE:AZN
52-week High/Low: 6,634.00p / 5,312.00p
Sector: Pharma & Biotech
Market Cap: £83,691.76 m
col 3
col 4
col 5
col 6

AstraZeneca RNS Announcements

Date Epic Announcement
15/07/2019 AZN Update on US regulatory decision for Farxiga
12/07/2019 AZN Imfinzi granted US Orphan Drug Designation for
01/07/2019 AZN Total Voting Rights
01/07/2019 AZN Forxiga receives positive EU CHMP opinion for
01/07/2019 AZN Fasenra receives positive EU CHMP opinion for self
27/06/2019 AZN Imfinzi improves overall survival at interim
19/06/2019 AZN Breztri Aerosphere (PT010) approved in Japan for
19/06/2019 AZN Bevespi Aerosphere approved by the Japanese
19/06/2019 AZN Lynparza approved in Japan for 1st-line
18/06/2019 AZN Lynparza approved in the EU for 1st-line
17/06/2019 AZN Calquence significantly prolonged the time patient
12/06/2019 AZN Publication of a Prospectus
06/06/2019 AZN Calquence Phase III ELEVATE-TN trial met primary
03/06/2019 AZN Total Voting Rights
03/06/2019 AZN Block listing Interim Review
03/06/2019 AZN Lynparza nearly doubled time patients lived with
10/05/2019 AZN Pooled analyses of the roxadustat global Phase III
08/05/2019 AZN Director/PDMR Shareholding
08/05/2019 AZN Director Declaration
08/05/2019 AZN Trastuzumab deruxtecan demonstrated clinically
07/05/2019 AZN Calquence PhIII ASCEND trial met primary endpoint
03/05/2019 AZN Qternmet XR approved in the US for type-2 diabetes
01/05/2019 AZN Total Voting Rights
01/05/2019 AZN Director/PDMR Shareholding
29/04/2019 AZN Lynparza receives positive EU CHMP opinion for 1st
26/04/2019 AZN Result of AGM
26/04/2019 AZN AZN: Q1 2019 Results
10/04/2019 AZN Lynparza approved in EU for the treatment of germl
04/04/2019 AZN Holding(s) in Company
03/04/2019 AZN Director/PDMR Shareholding

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use